Enhanced mucosal antibody production and protection against respiratory infections following an orally administered bacterial extract

Christian Pasquali, Olawale Salami, Manisha Taneja, Eva S. Gollwitzer, Aurélien Trompette, Celine Pattaroni, Koshika Yadava, Jacques Bauer, Benjamin John Marsland

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Secondary bacterial infections following influenza infection are a pressing problem facing respiratory medicine. Although antibiotic treatment has been highly successful over recent decades, fatalities due to secondary bacterial infections remain one of the leading causes of death associated with influenza. We have assessed whether administration of a bacterial extract alone is sufficient to potentiate immune responses and protect against primary infection with influenza, and secondary infections with either Streptococcus pneumoniae or Klebsiella pneumoniae in mice. We show that oral administration with the bacterial extract, OM-85, leads to a maturation of dendritic cells and B-cells characterized by increases in MHC II, CD86, and CD40, and a reduction in ICOSL. Improved immune responsiveness against influenza virus reduced the threshold of susceptibility to secondary bacterial infections, and thus protected the mice. The protection was associated with enhanced polyclonal B-cell activation and release of antibodies that were effective at neutralizing the virus. Taken together, these data show that oral administration of bacterial extracts provides sufficient mucosal immune stimulation to protect mice against a respiratory tract viral infection and associated sequelae.
Original languageEnglish
Article number41
Number of pages9
JournalFrontiers in Medicine
Volume1
DOIs
Publication statusPublished - 30 Oct 2014
Externally publishedYes

Cite this

Pasquali, Christian ; Salami, Olawale ; Taneja, Manisha ; Gollwitzer, Eva S. ; Trompette, Aurélien ; Pattaroni, Celine ; Yadava, Koshika ; Bauer, Jacques ; Marsland, Benjamin John. / Enhanced mucosal antibody production and protection against respiratory infections following an orally administered bacterial extract. In: Frontiers in Medicine. 2014 ; Vol. 1.
@article{de97efc371df4167a5f9ae4b84618230,
title = "Enhanced mucosal antibody production and protection against respiratory infections following an orally administered bacterial extract",
abstract = "Secondary bacterial infections following influenza infection are a pressing problem facing respiratory medicine. Although antibiotic treatment has been highly successful over recent decades, fatalities due to secondary bacterial infections remain one of the leading causes of death associated with influenza. We have assessed whether administration of a bacterial extract alone is sufficient to potentiate immune responses and protect against primary infection with influenza, and secondary infections with either Streptococcus pneumoniae or Klebsiella pneumoniae in mice. We show that oral administration with the bacterial extract, OM-85, leads to a maturation of dendritic cells and B-cells characterized by increases in MHC II, CD86, and CD40, and a reduction in ICOSL. Improved immune responsiveness against influenza virus reduced the threshold of susceptibility to secondary bacterial infections, and thus protected the mice. The protection was associated with enhanced polyclonal B-cell activation and release of antibodies that were effective at neutralizing the virus. Taken together, these data show that oral administration of bacterial extracts provides sufficient mucosal immune stimulation to protect mice against a respiratory tract viral infection and associated sequelae.",
author = "Christian Pasquali and Olawale Salami and Manisha Taneja and Gollwitzer, {Eva S.} and Aur{\'e}lien Trompette and Celine Pattaroni and Koshika Yadava and Jacques Bauer and Marsland, {Benjamin John}",
year = "2014",
month = "10",
day = "30",
doi = "10.3389/fmed.2014.00041",
language = "English",
volume = "1",
journal = "Frontiers in Medicine",
issn = "2296-858X",
publisher = "Frontiers Media",

}

Enhanced mucosal antibody production and protection against respiratory infections following an orally administered bacterial extract. / Pasquali, Christian ; Salami, Olawale; Taneja, Manisha ; Gollwitzer, Eva S.; Trompette, Aurélien; Pattaroni, Celine; Yadava, Koshika; Bauer, Jacques ; Marsland, Benjamin John.

In: Frontiers in Medicine, Vol. 1, 41, 30.10.2014.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Enhanced mucosal antibody production and protection against respiratory infections following an orally administered bacterial extract

AU - Pasquali, Christian

AU - Salami, Olawale

AU - Taneja, Manisha

AU - Gollwitzer, Eva S.

AU - Trompette, Aurélien

AU - Pattaroni, Celine

AU - Yadava, Koshika

AU - Bauer, Jacques

AU - Marsland, Benjamin John

PY - 2014/10/30

Y1 - 2014/10/30

N2 - Secondary bacterial infections following influenza infection are a pressing problem facing respiratory medicine. Although antibiotic treatment has been highly successful over recent decades, fatalities due to secondary bacterial infections remain one of the leading causes of death associated with influenza. We have assessed whether administration of a bacterial extract alone is sufficient to potentiate immune responses and protect against primary infection with influenza, and secondary infections with either Streptococcus pneumoniae or Klebsiella pneumoniae in mice. We show that oral administration with the bacterial extract, OM-85, leads to a maturation of dendritic cells and B-cells characterized by increases in MHC II, CD86, and CD40, and a reduction in ICOSL. Improved immune responsiveness against influenza virus reduced the threshold of susceptibility to secondary bacterial infections, and thus protected the mice. The protection was associated with enhanced polyclonal B-cell activation and release of antibodies that were effective at neutralizing the virus. Taken together, these data show that oral administration of bacterial extracts provides sufficient mucosal immune stimulation to protect mice against a respiratory tract viral infection and associated sequelae.

AB - Secondary bacterial infections following influenza infection are a pressing problem facing respiratory medicine. Although antibiotic treatment has been highly successful over recent decades, fatalities due to secondary bacterial infections remain one of the leading causes of death associated with influenza. We have assessed whether administration of a bacterial extract alone is sufficient to potentiate immune responses and protect against primary infection with influenza, and secondary infections with either Streptococcus pneumoniae or Klebsiella pneumoniae in mice. We show that oral administration with the bacterial extract, OM-85, leads to a maturation of dendritic cells and B-cells characterized by increases in MHC II, CD86, and CD40, and a reduction in ICOSL. Improved immune responsiveness against influenza virus reduced the threshold of susceptibility to secondary bacterial infections, and thus protected the mice. The protection was associated with enhanced polyclonal B-cell activation and release of antibodies that were effective at neutralizing the virus. Taken together, these data show that oral administration of bacterial extracts provides sufficient mucosal immune stimulation to protect mice against a respiratory tract viral infection and associated sequelae.

U2 - 10.3389/fmed.2014.00041

DO - 10.3389/fmed.2014.00041

M3 - Article

VL - 1

JO - Frontiers in Medicine

JF - Frontiers in Medicine

SN - 2296-858X

M1 - 41

ER -